European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis
Go back to European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 288.18 +1.77 (0.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $286.41 | 52 Week High | $109.10 | |||
| Open | $290.89 | 52 Week Low | $31.38 | |||
| Day High | $291.95 | P/E | N/A | |||
| Day Low | $285.26 | EPS | $-1.45 | |||
| Volume | 1,038,199 | |||||
